Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how the participant's disease (ovarian, primary
peritoneal serous, fallopian tube, or papillary serous endometrial cancer) responds to
additional treatment with Avastin (bevacizumab). Participants have already received Avastin
as part of maintenance therapy for their cancer. Maintenance therapy is a medical therapy
that is given to people to prevent a relapse. However, cancer may return after maintenance
therapy. This research study hopes to determine whether additional treatment with Avastin
will be effective in treating the participant's cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Dana-Farber Cancer Institute Genentech, Inc. Massachusetts General Hospital